Hematological Malignancies

PRIMA: Overall survival

Rituximab maintenance Observation

Overall survival 0.8 0.6 0.4 0.2 0 1.0

HR = 0.87 95% CI: 0.51–1.47 p = 0.60

0

6

12

18

24

30

36

42

48

54

60

Time (months)

Rituximab Observation Patients at risk

– –

505 513

499 507

492 501

483 492

474 472

365 381

246 243

108 97

22 26

1 0

Salles G, et al. Lancet 2011; 377:42–51.